Oral hormonal contraception should not be negated in BRCA1/BRCA2 mutation carriers not yet eligible for risk-reducing surgery because it significantly reduces the risk of developing ovarian cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.